Home Cart 0 Sign in  

[ CAS No. 39061-97-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 39061-97-7
Chemical Structure| 39061-97-7
Structure of 39061-97-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 39061-97-7 ]

Related Doc. of [ 39061-97-7 ]

Alternatived Products of [ 39061-97-7 ]

Product Details of [ 39061-97-7 ]

CAS No. :39061-97-7 MDL No. :MFCD07369246
Formula : C9H5ClN2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :ZRFUZDDJSQVQBY-UHFFFAOYSA-N
M.W : 208.60 Pubchem ID :11275808
Synonyms :

Calculated chemistry of [ 39061-97-7 ]

Physicochemical Properties

Num. heavy atoms : 14
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 55.58
TPSA : 58.71 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.69 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.5
Log Po/w (XLOGP3) : 2.65
Log Po/w (WLOGP) : 2.8
Log Po/w (MLOGP) : 1.23
Log Po/w (SILICOS-IT) : 0.86
Consensus Log Po/w : 1.81

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.27
Solubility : 0.113 mg/ml ; 0.000543 mol/l
Class : Soluble
Log S (Ali) : -3.53
Solubility : 0.061 mg/ml ; 0.000292 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.7
Solubility : 0.0412 mg/ml ; 0.000198 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.88

Safety of [ 39061-97-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 39061-97-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 39061-97-7 ]
  • Downstream synthetic route of [ 39061-97-7 ]

[ 39061-97-7 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 39061-97-7 ]
  • [ 58401-43-7 ]
Reference: [1] Journal of the American Chemical Society, 1951, vol. 73, p. 2413,2414
  • 2
  • [ 39061-97-7 ]
  • [ 105-53-3 ]
  • [ 79965-62-1 ]
Reference: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1988, vol. 24, # 10, p. 1149 - 1157[2] Khimiya Geterotsiklicheskikh Soedinenii, 1988, vol. 24, # 10, p. 1385 - 1393
  • 3
  • [ 50332-66-6 ]
  • [ 39061-97-7 ]
YieldReaction ConditionsOperation in experiment
93% With thionyl chloride In dichloromethane; N,N-dimethyl-formamideReflux; Cooling with ice The Intermediate 3-nitro-4-hydroxyquinoline 70 (18.7 g, 98.4 mmol) was suspended in dichloromethane (150 mL).
Thionyl chloride (17.2 mL, 236 mmol) and N,N-dimethylformamide (9.2 mL, 118 mmol) were added.
The reaction mixture was then heated at reflux overnight.
The reaction mixture was then poured in ice.
The layers were separated and the organic layer was washed with NaHCO3 solution, water and brine.
The organic layer was dried over Na2SO4, filtered and concentrated in vacuo.
The residue (20.52 g, yield 93percent) was used for the next step without any further purification.
Methyl 4-((3-nitroquinolin-4-ylamino)methyl)benzoate:
93% With thionyl chloride In dichloromethane; N,N-dimethyl-formamide 4-chloro-3-nitroquinoline
The Intermediate 3-nitro-4-hydroxyquinoline 15 (18.7 g, 98.4 mmol) was suspended in dichloromethane (150 mL).
Thionyl chloride (17.2 mL, 236 mmol) and DMF (9.2 mL, 118 mmol) were added.
The reaction mixture was then heated at reflux overnight.
The reaction mixture was then poured in ice.
The layers were separated and the organic layer was washed with NaHCO3 solution, water and brine.
The organic layer was dried over Na2SO4, filtered and concentrated in vacuo.
The residue (20.52 g, yield 93percent) was used for the next step without any further purification.
81% for 0.5 h; Heating / reflux 3-Nitro-4-chIoroquinoIine (compound 6); Compound 6 was prepared as described elsewhere [Van Galen, P. J. M. et. al. 1- H-imidazo[4,5-c]quinolin-4-amines: Novel Non-Xanthine Adenosine Antagonists. J. Med. Chem. 1991, 34, 1202-1206]. In brief, 3-Nitro-4-hydroxyquinoline 5 (5.7 g, 30 mmol) was added to phosphorus oxychlσride (70.0 g, 41.2 ml, 450 mmol) with stirring. <n="22"/>The mixture was refluxed for 30 minutes. After cooling the solvent was poured over crushed ice while stirring. After 1 hour the solid that was formed was filtered off, washed with cold water and dissolved in ethyl acetate. The solution was extracted with ice-cold NaOH (1 M) till ρH= 8-9 and dried over MgSO4. The solvent was evaporated and the residue was dried. Yield: 5.05 g (81percent). Mp.: 118M19 αC. 1H NMR (DMSO- d6): δ 7.94-8.11 (m, 2H, Ar); 8.25 (d, IH5 J= 8.0 Hz5 Ar); 8.47 (d, IH, J= 9.5 Hz, Ar); 9.42 (s, IH, Ar).
2.3 g With trichlorophosphate In N,N-dimethyl-formamide at 100℃; for 0.25 h; Phosphorus oxychloride (2.5 mL, 27 mmol) was added dropwise to a mixture of 3-nitroquinolin-4-ol (4.6 g, 24 mmol) and 100 mL of DMF. The mixture was heated at 100 °C for 15 min, and then poured onto stirred ice. The slurry was neutralized with solid NaHC03, and the precipitate was filtered and washed with saturated NaHC03 and H20. The filtrate was taken up in DCM, dried over anhydrous Na2S04, and concentrated to give 2.3 g of solid.

Reference: [1] Patent: EP2674170, 2013, A1, . Location in patent: Paragraph 0228
[2] Patent: US2014/141033, 2014, A1, . Location in patent: Page/Page column
[3] Journal of Medicinal Chemistry, 1991, vol. 34, # 3, p. 1202 - 1206
[4] Journal of Medicinal Chemistry, 2006, vol. 49, # 11, p. 3354 - 3361
[5] Patent: WO2007/89507, 2007, A1, . Location in patent: Page/Page column 20-21
[6] RSC Advances, 2016, vol. 6, # 81, p. 77717 - 77734
[7] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 8, p. 2211 - 2214
[8] Journal of the Chemical Society, 1948, p. 1284,1290
[9] Journal of the American Chemical Society, 1951, vol. 73, p. 2413,2414
[10] Yakugaku Zasshi, 1952, vol. 72, p. 767,770[11] Chem.Abstr., 1954, p. 2711
[12] Journal of the American Chemical Society, 1947, vol. 69, p. 365,370
[13] Yakugaku Zasshi, 1952, vol. 72, p. 1109[14] Chem.Abstr., 1953, p. 6946
[15] Pharmaceutical Bulletin, 1957, vol. 5, p. 56,60
[16] Journal of Medicinal Chemistry, 1989, vol. 32, # 11, p. 2474 - 2485
[17] Journal of Medicinal Chemistry, 2005, vol. 48, # 10, p. 3481 - 3491
[18] Patent: WO2003/97641, 2003, A2, . Location in patent: Page/Page column 51
[19] Patent: WO2005/18551, 2005, A2, . Location in patent: Page/Page column 206-207
[20] Patent: US6348462, 2002, B1, . Location in patent: Page column 21
[21] Patent: US6348462, 2002, B1, . Location in patent: Page column 34
[22] Patent: US2011/136801, 2011, A1, . Location in patent: Page/Page column 21
[23] Patent: WO2014/120995, 2014, A2, . Location in patent: Page/Page column 173
[24] Patent: JP5837549, 2015, B2, . Location in patent: Paragraph 0101
[25] Patent: WO2017/184735, 2017, A1, . Location in patent: Page/Page column 63; 64
[26] Patent: CN108003153, 2018, A, . Location in patent: Paragraph 0064; 0070
[27] Patent: WO2005/18551, 2005, A2, . Location in patent: Page/Page column 206-207
  • 4
  • [ 611-36-9 ]
  • [ 39061-97-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 10, p. 3481 - 3491
[2] Journal of the American Chemical Society, 1951, vol. 73, p. 2413,2414
[3] Patent: US2011/136801, 2011, A1,
[4] Patent: EP2674170, 2013, A1,
[5] Patent: WO2014/120995, 2014, A2,
[6] Patent: JP5837549, 2015, B2,
[7] Patent: WO2017/184735, 2017, A1,
[8] Patent: CN108003153, 2018, A,
  • 5
  • [ 121845-92-9 ]
  • [ 39061-97-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2006, vol. 49, # 11, p. 3354 - 3361
[2] Journal of Medicinal Chemistry, 1989, vol. 32, # 11, p. 2474 - 2485
[3] Journal of the American Chemical Society, 1947, vol. 69, p. 365,370
  • 6
  • [ 118-92-3 ]
  • [ 39061-97-7 ]
Reference: [1] Journal of the American Chemical Society, 1947, vol. 69, p. 365,370
  • 7
  • [ 125836-07-9 ]
  • [ 39061-97-7 ]
Reference: [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 14, p. 2844 - 2851
  • 8
  • [ 2099-63-0 ]
  • [ 39061-97-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2006, vol. 49, # 11, p. 3354 - 3361
  • 9
  • [ 56-57-5 ]
  • [ 39061-97-7 ]
Reference: [1] Pharmaceutical Bulletin, 1957, vol. 5, p. 56,60
  • 10
  • [ 39061-97-7 ]
  • [ 99010-24-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 10, p. 3481 - 3491
[2] Patent: WO2014/120995, 2014, A2,
  • 11
  • [ 39061-97-7 ]
  • [ 99010-64-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 10, p. 3481 - 3491
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 39061-97-7 ]

Imiquimod Related Intermediates

Chemical Structure| 6630-33-7

[ 6630-33-7 ]

o-Bromobenzaldehyde

Chemical Structure| 99010-24-9

[ 99010-24-9 ]

1-Isobutyl-1H-imidazo[4,5-c]quinoline

Chemical Structure| 50332-66-6

[ 50332-66-6 ]

3-Nitroquinolin-4-ol

Chemical Structure| 132521-66-5

[ 132521-66-5 ]

2,4-Dichloro-3-nitroquinoline

Chemical Structure| 611-36-9

[ 611-36-9 ]

4-Hydroxyquinoline

Related Functional Groups of
[ 39061-97-7 ]

Chlorides

Chemical Structure| 723281-72-9

[ 723281-72-9 ]

6-Bromo-4-chloro-3-nitroquinoline

Similarity: 0.89

Chemical Structure| 132521-66-5

[ 132521-66-5 ]

2,4-Dichloro-3-nitroquinoline

Similarity: 0.87

Chemical Structure| 39487-89-3

[ 39487-89-3 ]

4-Chloro-3-nitro-8-(trifluoromethyl)quinoline

Similarity: 0.86

Chemical Structure| 23833-99-0

[ 23833-99-0 ]

4-Chloro-8-nitroquinoline

Similarity: 0.83

Chemical Structure| 58401-43-7

[ 58401-43-7 ]

4-Chloroquinolin-3-amine

Similarity: 0.83

Nitroes

Chemical Structure| 723281-72-9

[ 723281-72-9 ]

6-Bromo-4-chloro-3-nitroquinoline

Similarity: 0.89

Chemical Structure| 132521-66-5

[ 132521-66-5 ]

2,4-Dichloro-3-nitroquinoline

Similarity: 0.87

Chemical Structure| 39487-89-3

[ 39487-89-3 ]

4-Chloro-3-nitro-8-(trifluoromethyl)quinoline

Similarity: 0.86

Chemical Structure| 23833-99-0

[ 23833-99-0 ]

4-Chloro-8-nitroquinoline

Similarity: 0.83

Chemical Structure| 40106-98-7

[ 40106-98-7 ]

4-Chloro-5-nitroquinoline

Similarity: 0.83

Related Parent Nucleus of
[ 39061-97-7 ]

Quinolines

Chemical Structure| 723281-72-9

[ 723281-72-9 ]

6-Bromo-4-chloro-3-nitroquinoline

Similarity: 0.89

Chemical Structure| 132521-66-5

[ 132521-66-5 ]

2,4-Dichloro-3-nitroquinoline

Similarity: 0.87

Chemical Structure| 39487-89-3

[ 39487-89-3 ]

4-Chloro-3-nitro-8-(trifluoromethyl)quinoline

Similarity: 0.86

Chemical Structure| 23833-99-0

[ 23833-99-0 ]

4-Chloro-8-nitroquinoline

Similarity: 0.83

Chemical Structure| 58401-43-7

[ 58401-43-7 ]

4-Chloroquinolin-3-amine

Similarity: 0.83